Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Clinical management of advanced gastric cancer: The role of new molecular drugs.
[esophageal carcinoma]
Gastric
cancer
is
the
fourth
most
common
malignant
neoplasm
and
the
second
leading
cause
of
death
for
cancer
in
Western
countries
with
more
than
2000
0
new
cases
yearly
diagnosed
in
the
United
States
.
Surgery
represents
the
main
approach
for
this
disease
but
,
notwithstanding
the
advances
in
surgical
techniques
,
we
observed
a
minimal
improvement
in
terms
of
overall
survival
with
a
significant
increasing
of
relapsing
disease
rates
.
Despite
the
development
of
new
drugs
has
significantly
improved
the
effectiveness
of
chemotherapy
,
the
prognosis
of
patients
with
unresectable
or
metastatic
gastric
adenocarcinoma
remains
poor
.
Recently
,
several
molecular
target
agents
have
been
investigated
;
in
particular
,
trastuzumab
represents
the
first
target
molecule
showing
improvements
in
overall
survival
in
human
epithelial
growth
factor
2
-
positive
gastric
cancer
patients
.
New
molecules
targeting
vascular
epithelial
growth
factor
,
mammalian
target
of
rapamycin
,
and
anti
hepatocyte
growth
factor
-c-
Met
pathway
are
also
under
investigation
,
with
interesting
results
.
Anyway
,
it
seems
necessary
to
select
more
accurately
the
population
to
treat
with
new
agents
by
the
identification
of
new
biomarkers
in
order
to
optimize
the
results
.
In
this
paper
we
review
the
actual
"
scenario
"
of
targeted
treatments
,
also
focusing
on
the
new
agents
in
development
for
gastric
cancer
and
gastro-
esophageal
carcinoma
,
discussing
their
efficacy
and
potential
applications
in
clinical
practice
.
Diseases
Validation
Diseases presenting
"the second leading cause of death for cancer in western countries with more than 20000 new cases yearly diagnosed in the united states"
symptom
esophageal carcinoma
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom